1. Home
  2. MD vs EYPT Comparison

MD vs EYPT Comparison

Compare MD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$21.09

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.72

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
EYPT
Founded
1979
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
MD
EYPT
Price
$21.09
$13.72
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$21.00
$28.75
AVG Volume (30 Days)
564.0K
1.1M
Earning Date
02-19-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.91
N/A
Revenue
$1,922,442,000.00
$42,339,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
$10.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.84
$3.91
52 Week High
$24.99
$19.11

Technical Indicators

Market Signals
Indicator
MD
EYPT
Relative Strength Index (RSI) 46.94 41.74
Support Level $20.55 $12.11
Resistance Level $21.58 $13.68
Average True Range (ATR) 0.70 1.00
MACD -0.02 -0.09
Stochastic Oscillator 42.34 34.20

Price Performance

Historical Comparison
MD
EYPT

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: